Microbix Biosystems Inc. has seen a notable decline in its stock price this week, reflecting broader market trends and company-specific developments.
Microbix Biosystems Inc. (MBX.TO) closed at C$0.29 on Friday, maintaining stability despite a 9.38% drop over the past week. The company's recent performance and strategic initiatives have kept investors attentive, particularly in light of its latest earnings report and future outlook.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$39.72M
52W high
$0.33
52W low
$0.21
1W change
-9.38%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 37.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+37.9% Upside
Current Price
C$0.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
51.0%
Annualized
90-Day Vol
51.0%
Annualized
Trend (90d)
+14.7%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.30 | C$0.25 – C$0.35 |
| 60 trading days | C$0.30 | C$0.23 – C$0.39 |
| 90 trading days | C$0.31 | C$0.23 – C$0.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the company's recent earnings growth and future presentations, alongside its current valuation metrics and market sentiment, when evaluating Microbix Biosystems Inc. stock.
Microbix Biosystems Inc. Reports 17% Revenue Growth for Q3 Fiscal 2026
The company reported revenues of $4.1 million for Q3 Fiscal 2026, reflecting efforts to rebuild following previous client setbacks.
Bull case
The company reported a 17% increase in revenue compared to the same quarter last year, indicating a potential recovery. Analysts are optimistic, with an average target price suggesting the stock could rise further.
Bear case
Despite the revenue growth, the company is still operating at a loss, with a profit margin of -31.7%. This financial instability may deter risk-averse investors.
Recent Price Action
Microbix Biosystems Inc. (MBX.TO) has closed at C$0.29, unchanged for the day but reflecting a 9.38% decline over the past week. Year-to-date, the stock has shown a positive return of 20.83%. The company’s recent earnings report, released on August 13, 2026, highlighted a revenue growth of 17%, which may have contributed to investor interest despite the recent price drop.
Company News and Developments
Advertisement
In its latest earnings report, Microbix announced revenues of $4.1 million for Q3 Fiscal 2026, demonstrating a recovery from previous setbacks. The company attributed this growth to strategic efforts aimed at rebuilding its client base and enhancing product offerings. No new major announcements have been released this week, but the company is scheduled to discuss its Q2 Fiscal 2026 results in a webinar on May 14, 2026.
Technical Picture
Looking at the technical indicators, Microbix is currently trading below its 50-day moving average of C$0.30, indicating a short-term bearish sentiment. However, it is above its 200-day moving average of C$0.26, suggesting a longer-term bullish trend. The stock’s 52-week range is C$0.21 to C$0.33, placing it at 67% of its range. With a beta of 0.57, the stock exhibits lower volatility compared to the market.
Insider Activity
No recent insider trading activity has been reported for Microbix Biosystems Inc. This lack of insider transactions may suggest stability in management perspectives regarding the company's future.
Price Action Summary
The last close for Microbix Biosystems Inc. was C$0.29, showing no change for the day. Investors will be watching closely for any updates from the upcoming earnings discussion and further developments in the company's strategic initiatives.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
